ライフサイエンスコーパス: cell-based assay

1 rse chemical structures was screened using a cell-based assay.

2 ed phosphorylation of the EphA4 protein in a cell-based assay.

3 Tau prions were measured using a cell-based assay.

4 ompounds in complex natural mixtures using a cell-based assay.

5 he mouse neutralization assay and a neuronal cell-based assay.

6 hod; and LRP4 antibodies were tested using a cell-based assay.

7 on of H3K9Me3 and H3K4Me3 demethylation in a cell-based assay.

8 one mAbs revealed inhibitory properties in a cell-based assay.

9 d, primary mutations were identified using a cell-based assay.

10 A mutations impaired transport activity in a cell-based assay.

11 e-activated cell sorting, a live transfected cell-based assay.

12 rgenic functionality was then assessed using cell-based assay.

13 ovided an acceptable detection limit for the cell-based assay.

14 tested for NMDAR IgG antibodies using a live cell-based assay.

15 it nanomolar potency in both biochemical and cell based assays.

16 ation (pAKT) in PI3Kdelta-dependent in vitro cell based assays.

17 t also apply to drug studies with other stem cell-based assays.

18 zers, which was confirmed experimentally via cell-based assays.

19 o the observed [Formula: see text] values in cell-based assays.

20 y, which we demonstrate biochemically and in cell-based assays.

21 igh-throughput screening using enzymatic and cell-based assays.

22 efficient end joining and radioresistance in cell-based assays.

23 ns the development of specific and sensitive cell-based assays.

24 A receptor, and the AMPA receptor using live cell-based assays.

25 , many of which had bactericidal activity in cell-based assays.

26 further characterized using biochemical and cell-based assays.

27 le variants of EBOV and other filoviruses in cell-based assays.

28 l four serotypes with low micromolar EC50 in cell-based assays.

29 ce the induction and dynamics of vimentin in cell-based assays.

30 ase models at the speed and cost of in vitro cell-based assays.

31 ormation and attenuate virion infectivity in cell-based assays.

32 situ hybridization, immunohistochemistry and cell-based assays.

33 nd can be activated specifically by NPY-8 in cell-based assays.

34 e of antibodies to AQP4, MOG, and GlyR using cell-based assays.

35 inhibitors of the enzyme in biochemical and cell-based assays.

36 , correlates directly with their efficacy in cell-based assays.

37 heir reported loss-of-function phenotypes in cell-based assays.

38 tly (IC50 < 100 nm) inhibit Jak3 activity in cell-based assays.

39 antibody positivity, which was confirmed by cell-based assays.

40 against HIV-1ADA-M, HSV-2, and HPV16 PsV in cell-based assays.

41 oteases cathepsins and renin and activity in cell-based assays.

42 rum aquaporin-4 antibodies are detected with cell-based assays.

43 g and reduce prion levels was established in cell-based assays.

44 ere further characterized in biochemical and cell-based assays.

45 the absence of the activating EGF ligand in cell-based assays.

46 DA from serum samples prior to conduction of cell-based assays.

47 usogenicity and Shiga toxin Vero toxicity in cell-based assays.

48 ent in vitro, do not always show efficacy in cell-based assays.

49 in vitro and to impair viral replication in cell-based assays.

50 inst HIV-1 vectors harboring wild-type IN in cell-based assays.

51 rformed using brain immunohistochemistry and cell-based assays.

52 of which cannot be adequately assessed with cell-based assays.

53 RNA packaging to a DeltaNC HIV-1 variant in cell-based assays.

54 lar concentrations, with minimal toxicity in cell-based assays.

55 maging, proteomic, genetic, metabolomic, and cell-based assays.

56 so exhibited promising antiviral activity in cell-based assays.

57 ed kinases to drug treatment in patients and cell-based assays.

58 zoRosi, which were confirmed to be active in cell-based assays.

59 ar inhibition in DENV RNA polymerization and cell-based assays.

60 ted their MT binding properties in mammalian cell-based assays.

61 e high potency of RDV against RNA viruses in cell-based assays.

62 e respective activity of JNK1 and IKKbeta in cell-based assays.

63 ase mu (Pol mu) in steady-state kinetics and cell-based assays.

64 S correlate with activity in biochemical and cell-based assays.

65 s effective against norovirus replication in cell-based assays.

66 ate of antibody-bound MET receptor in single cell-based assays.

67 characterized using different approaches and cell-based assays.

68 l-based assay (1.5%), and in CSF controls by cell-based assay (0.9%).

69 rum controls by tissue-based assay (0.5%) or cell-based assay (1.5%), and in CSF controls by cell-bas

70 In cell-based assays, 1.0 nM of Pz-1 strongly inhibited pho

71 In cell-based assays, ACY-738 increased the relative associ

72 Here, using biochemical and cell-based assays along with isothermal titration calori

73 Cell-based assays also indicate that bVP24 exhibits decr

74 henotype, (2) MOG-IgG seropositivity by live cell-based assay and (3) MRI lesion(s) of brainstem, cer

75 Our results demonstrate that the cell-based assay and GO enzyme assay developed in this s

76 partate receptor using a flow cytometry live cell-based assay and immunolabeling of murine primary ne

77 cosylation significantly decreased ADCC in a cell-based assay and suppressed antibody-mediated cell k

78 e ability of each mutant to bind RetGC1 in a cell-based assay and to activate it in vitro.

79 ve similarly to ZMC1 in both biophysical and cell-based assays and are heretofore named ZMC2 (NSC3197

80 Furthermore, using cell-based assays and chemoproteomics, we demonstrate th

81 their biologic properties were determined in cell-based assays and confocal microscopy.

82 e highly useful bioluminescent reporters for cell-based assays and drug discovery.

83 We validate this approach in cell-based assays and in a mouse model of TCR gene trans

84 The lead compound had activity in cell-based assays and in a mouse xenograft efficacy mode

85 In addition, in vitro cell-based assays and in silico analyses of TONSL struct

86 However, using cell-based assays and integrated proteomics, phosphoprot

87 uble-strand break (DSB) repair using several cell-based assays and proteomic interaction network anal

88 Here, using cell-based assays and tau transgenic mice harboring an a

89 This includes functional cell-based assays and the evaluation of molecular expres

90 annel blocking ability were determined using cell-based assays and two-electrode voltage clamp (TEVC)

91 Cell-based assays and unique strain devices were used to

92 nd Mycbp positively regulate Hh signaling in cell-based assays and zebrafish.

93 Using structure-guided design, several cell based assays, and microdosed positron emission tomo

94 sing immunoprecipitation, mass spectrometry, cell-based assay, and analysis of antibody effects in cu

95 ty to trastuzumab, has similar activity in a cell-based assay, and can arrest tumor growth in a mouse

96 ed for hGLUT family members, hGLUT1-4, using cell-based assays, and compared with homology models for

97 ch, including clinical analysis of patients, cell-based assays, and computational studies, we charact

98 nerve and isolated airway neuron tissue- and cell-based assays, and in vivo single-fiber recording el

99 AT3 with selectivity over STAT5 and STAT1 in cell-based assays, and increases the apoptotic rate of c

100 4A9, as quantified via ELISA, hemolytic, and cell-based assays, and showed improved solubility, as me

101 ship (SAR) studies utilizing biochemical and cell-based assays, and structure-based drug design is re

102 AP isoforms (alpha, varepsilon, or kappa) by cell-based assays; and (3) clinical data available.

103 We present a high content multiwell plate cell-based assay approach to quantify protein interactio

104 t aspect of mathematical models as in vitro, cell-based assays are expected to provide the bulk of ex

105 ssociated with early AMVR, and that in vitro cell-based assays are needed to improve risk assessments

106 nterest in the HIV vaccine field but current cell-based assays are usually difficult to reproduce acr

107 lar to upper nanomolar inhibitory potency in cell-based assays, are selective against other serine pr

108 displayed substantially enhanced potency in cell-based assays, as well as in murine tumor xenograft

109 zymes, we developed a robust and automatable cell-based assay based on fluorophore- and fluorescence-

110 Here, we use a combination of cell-based assays, biophysical analysis, and atomic forc

111 r all of these possibilities in vitro and in cell-based assays, but moving RET into intact animals ha

112 tants in a cellular milieu, we established a cell-based assay by stably expressing 2 reporter protein

113 Together these data suggest that cell based assays can reveal subtle but clinically relev

114 orbent assay (ELISA) and a fixed transfected cell-based assay (CBA), we tested AQP4-IgG in a northern

115 03/114 patients with available serum on live cell-based assays (CBA) for aquaporin-4 (AQP4)-M23-IgG a

116 , we used rat brain immunohistochemistry and cell-based assays (CBA) with fixed or live NMDA receptor

117 Cell-based assays (CBAs) were shown to improve detection

118 S autoimmune disorders, using fixed and live cell-based assays (CBAs).

119 intracellular delivery should be useful for cell-based assays, cellular imaging applications and the

120 onclude that acute transcriptomic changes in cell-based assays combined with drug substructures are p

121 However, resulting candidate gene lists from cell-based assays comprise diverse effectors, both direc

122 Cell-based assays confirm that the pericellular hydrogel

123 r matrix while surface plasmon resonance and cell-based assays confirmed that ACE-083 binds and poten

124 Cell-based assays confirmed this hypothesis, linking the

125 Cell-based assays corroborated these findings in mice.

126 itional repair function of NONO, revealed in cell-based assays, could involve RNA interaction.

127 We then successfully applied our approach on cell-based assay data and on tissue images.

128 Cell-based assays demonstrate nanomolar inhibition (EC(5

129 Cell-based assays demonstrate that S1P can rapidly up-re

130 Cell based assays demonstrated that the optimized inhibi

131 Cell-based assays demonstrated that HUWE1 interacts with

132 Furthermore, cell-based assays demonstrated that some of the caffeine

133 alidate mitoxantrone in orthogonal mammalian cell-based assays, demonstrating that our screening appr

134 tarate, both in tumors and in a heterologous cell-based assay designed to functionally evaluate DLST

135 In addition, most functional cell-based assays designed to characterize the neutraliz

136 Confocal microscopy studies and cell-based assays disclosed that after roseltide rT7 pen

137 It is anticipated that other fast-response cell-based assays (e.g., other ion flux assays) can be i

138 ts S1P-induced receptor internalization in a cell-based assay (EC50 = 0.05 muM), but has poor physica

139 In cell-based assays, either hepcidin from hepatocytes or e

140 These cell-based assays elucidate this important aspect of tra

141 We have used an established cell-based assay employing a PC12 cell line overexpressi

142 RNA-sequencing, mass spectrometry, and cell-based assays employing primary adult rat ventricula

143 Miniaturization of cell-based assays enables the analysis of secreted compo

144 in to test this hypothesis we utilised human cell-based assays, ex vivo murine BALF, in vivo pre-clin

145 In recent years, in vitro cell-based assays, ex vivo palate cultures, and genetica

146 Although cell-based assays exist, rapid and cost-efficient high-c

147 ug Administration-approved drugs, in a novel cell-based assay, followed by secondary screens in brain

148 ass spectrometry-based high-throughput whole cell-based assay for aldosterone synthesis.

149 Thereby a complete cell-based assay for efficient drug screening is perform

150 We have established an NK-92 cell-based assay for IFN-gamma release, identified resid

151 screen of a human miRNA mimetic library in a cell-based assay for invasion by the melanoma cell line

152 Here, we introduce a cell-based assay for protein-protein interaction analysi

153 hable kinases, we established an all-optical cell-based assay for screening inhibitors, uncovered a d

154 ough heterologous expression of receptors in cell-based assays for 9 endogenous ligands.

155 The other two patients tested negative by cell-based assays for all known CNS antigens.

156 Cell-based assays for all other known CNS antigens were

157 d underscores the utility of high-resolution cell-based assays for assessment of compound efficacy.

158 ished atlastin1/SPG3A disease variants using cell-based assays for atlastin-mediated ER network forma

159 ies of envelope assembly have benefited from cell-based assays for detecting protein-protein interact

160 enomenon of glyco-stress provides convenient cell-based assays for developing a new class of inhibito

161 e National Cancer Center were analysed using cell-based assays for MOG-IgG and aquaporin-4 immunoglob

162 excitotoxicity, hindering the development of cell-based assays for NMDAR drug discovery.

163 vitro assays, including enzymatic tests and cell-based assays for viral replication and cellular gro

164 ng sites on G protein-coupled receptors in a cell-based assay format.

165 ania NMT, across 68 compounds in enzyme- and cell-based assay formats.

166 In vitro cell-based assays further proved the validity of the Dri

167 In recent years, cell-based assays have gained more and more popularity s

168 Humoral-based and cell-based assays have identified antibodies against mye

169 Moreover, biochemical and cell-based assays identify oxidative stress as a signall

170 g of the endogenous LGI4 transcript and in a cell-based assay impaired the secretion of truncated LGI

171 vity, and provides an important standardized cell-based assay in the field.

172 PR-mediated loss-of-function screens using a cell-based assay in which mitosis is consistently distur

173 with first-episode psychosis using classical cell-based assays in three labs and a single molecule-ba

174 mined the function of these structures using cell-based assays, in vitro translation systems, and in

175 nvestigated ghrelin signaling in a number of cell-based assays, including Ca(2+) mobilization, serum

176 g a combination of in vitro biochemistry and cell-based assays, including chemically induced dimeriza

177 ryptic inhibited ligand signaling in various cell-based assays, including SMAD-mediated luciferase re

178 e PORCN inhibitors that were discovered with cell-based assays indeed target human PORCN.

179 Biophysical analyses in combination with cell-based assays indicate that hRpn13 binds preferentia

180 Cell-based assays indicated that the hydrolysates presen

181 Further evaluation using cell-based assays, indirectly linked to galectin-3 inhib

182 interacting ArfGAP 1) gene using functional cell-based assays involving coexpression of GIT1 and PAK

183 Cell-based assay is a useful procedure in the routine di

184 sting all potentially mutagenic compounds in cell-based assays is tedious and costly.

185 ves was synthesized, and SAR analysis, using cell-based assays, led to the discovery of 28 (AMG 925),

186 In live cell-based assays, LGI1 epitope recognition was examined

187 Cell-based assays, like the cellular antioxidant activit

188 In cell-based assays, matriptase was a potent activator of

189 AZD6738, we have developed multi-parametric cell based assays measuring DNA damage and cell cycle tr

190 sing 21 assays including live (n=3) or fixed cell-based assays (n=10), flow cytometry (n=4), immunohi

191 e for NPYLR7, we performed a high-throughput cell-based assay of 265,211 compounds and isolated six h

192 Proteasome-Glo is a homogeneous cell-based assay of proteasomal chymotrypsin-like, tryps

193 Cell-based assays of BBB permeation, neurotoxicity, and

194 creased potency in kinase, thermal shift, or cell-based assays of BMP signaling and transcription, as

195 dentify a candidate gene, ALG9, and in vitro cell-based assays of PC1 protein maturation to functiona

196 We describe here two cell-based assays of tau inclusion formation that we emp

197 Cell-based assays of tubulin dynamics reveal various eff

198 tion of dengue and West Nile virus titers in cell-based assays of virus replication, with an EC50 val

199 Through cell-based assays on several human-derived cell lines, w

200 -tetramethylindocarbocyanine perchlorate LDL cell-based assays on the stable knockdown HepG2 and Huh7

201 iomolecular labels and tags while label-free cell-based assays only offer holistic information about

202 Using two orthogonal cell-based assays, our study also found differential via

203 Using live cell-based assays, Positive and Low Positive antibodies

204 showed dose-dependent inhibition of SOCE in cell-based assay, probably through interacting with the

205 dentified one residue (position 170) that in cell-based assays profoundly altered pathway selectivity

206 istinct clinical phenotypes; the established cell-based assay provides a powerful tool for studying t

207 rement of the rate of the self-assembly in a cell-based assay provides precise assessment of the cell

208 Cell-based assays revealed no direct correlation between

209 In vitro and cell-based assays revealed that the CNAbeta1-containing

210 tested BCRs were autoreactive, although the cell-based assay sensitively detects feeble Ag recogniti

211 Cell-based assays show selective PARG inhibition and PAR

212 Cell-based assays show that expression of full-length HP

213 Our biophysical and cell-based assays show that the secondary interface cont

214 Cell-based assays showed that CacyBP/SIP forms a homodim

215 Cell-based assays showed that OsPHT2;1 localized to the

216 A cell-based assay shows that nonhomologous end joining (N

217 el recombinant LCMV and its use to develop a cell-based assay suitable for HTS to rapidly identify in

218 ly closed circular (ccc) DNA, we developed a cell-based assay supporting synchronized and rapid cccDN

219 Cell-based assay supports the physiological relevance of

220 They use this cell-based assay system to help explain the clinical man

221 ose studies relied on cell-free or accessory cell-based assay systems that do not accurately reflect

222 In a cell-based assay, TAF was 35- and 24-fold and TDF was 10

223 CD2 monoubiquitination in biochemical and/or cell-based assays tended to show earlier onset of hemato

224 and exhibits higher inhibitory activities in cell-based assays than biochemical assays.

225 To measure the toxin activity, we used a cell based assay that makes quantification more robust a

226 We validated that a cell-based assay that measures TNF-alpha production by C

227 We have developed a microscale cell-based assay that responds to complex pro- and antia

228 PAPP-A cleavage of IGFBP-4, and we show in a cell-based assay that STC1 effectively antagonizes PAPP-

229 To address this challenge, we developed a cell-based assay that utilizes a premalignant phenotype

230 This result underscores the importance of cell-based assays that capture chemical cross-talk occur

231 vide an overview of established and emerging cell-based assays that exploit fluorescence for studies

232 Traditional methods rely on cell-based assays that lack reproducibility and accuracy

233 ultidisciplinary development of in vitro and cell-based assays that more appropriately reflect the ph

234 nking studies, microscale thermophoresis and cell-based assays that support a role of LIMP-2 in chole

235 Here, we demonstrate in vitro and in cell-based assays that the viral RNA polymerase, NS5, in

236 Here, we demonstrate, using in vitro and cell-based assays, that dCA directly binds to SIV Tat's

237 on-coding region we have further developed a cell-based assay (the 3'CRE-REP assay) to yield recombin

238 In cell-based assays, the compounds show growth inhibition

239 In CME and growth inhibition cell-based assays, the data obtained was consistent with

240 cted mutagenesis, inhibition experiments and cell-based assays, the structure also provides an insigh

241 surface of beads, and increase uniformity in cell-based assays through automation.

242 Here we present a high-throughput, cell-based assay to identify anticodon engineered transf

243 In this study, we used a cell-based assay to investigate the autoreactivity of me

244 We describe a cell-based assay to overcome this challenge, based on GP

245 pha1-3-fucosyltransferase, we develop a host-cell-based assay to probe glycan-mediated influenza A vi

246 Here we describe a reporter cell-based assay to quantify inducible, replication-comp

247 We developed a cell-based assay to screen the ability of CCG258747 and

248 We have developed a cell-based assay to study recombination of EV-A71 based

249 Cell-based assays to assess the effect of ADH-41 on Abet

250 quantitative polymerase chain reactions and cell-based assays to confirm the main effects and found

251 X-ray crystallography, NMR spectroscopy, and cell-based assays to demonstrate that recruitment and ph

252 We also used a variety of cell-based assays to dissect the specific step of the HC

253 These findings were supported by in vitro cell-based assays to evaluate cell viability, induction

254 We tested all four TSCs in a number of cell-based assays to examine mutant p53 reactivation and

255 In this study, we used cell-based assays to examine the effect of two CA bindin

256 response performance and off-target effects, cell-based assays to identify compounds that attenuate V

257 We used surface plasmon resonance and cell-based assays to investigate this important IFN-beta

258 a tetrameric assembly, which is shown by our cell-based assays to regulate the endocytosis of RET.

259 chemistry using live hippocampal neurons and cell-based assays to test for anti-N-methyl-d-aspartate

260 nity to assimilate biochemical findings with cell-based assays to uncover new insights into this dece

261 opment as well as the establishment of human cell-based assays to validate therapeutic strategies ex

262 uctural analysis, as well as biophysical and cell-based assays, to show that the DEP domain of Dishev

263 Using biochemical and cell-based assays together with mutagenesis, we show tha

264 Most cell-based assays use one signaling pathway or reporter

265 Here, we report the development of a cell-based assay used with a library of human miRNA mimi

266 ere comprehensively tested for NSA-abs, with cell-based assays used for leucine-rich glioma-inactivat

267 assay, and selectively inhibited SOAT1 in a cell-based assay using SOAT1-/SOAT2-CHO cells.

268 Cell-based assays using C-terminal-truncated human MOG a

269 nd daidzein on adipogenesis were examined in cell-based assays using the 3T3-L1 cell model.

270 ely 1 muM and selectivity indices of >100 in cell-based assays using western equine encephalitis viru

271 However, some heterogeneity between cell-based assays was clearly observed, highlighting the

272 nst norovirus 3C-like protease in enzyme and cell-based assays was determined.

273 Using this cell-based assay, we screened 102 candidate factors invo

274 R) and catalytic (C) spines with kinetic and cell-based assays, we discovered a major regulatory mech

275 rticipants, disease modeling in rodents, and cell-based assays, we examined whether S1P signaling may

276 First, using two complementary cell-based assays, we exclude endosomal rupture as the p

277 of bioinformatics, biochemical analysis, and cell-based assays, we identify here specific histone mod

278 Combining in vitro reconstitution and cell-based assays, we now identify dual mechanisms throu

279 Using engineered mouse models and cell-based assays, we provide evidence that the Tug1 loc

280 icroscopy, structure-guided mutagenesis, and cell-based assays, we reveal the binding interactions be

281 Using cell-based assays, we show here that PIs can directly in

282 ynamics simulations, biochemical assays, and cell-based assays, we showed that the mutation is a bona

283 Positive or Low Positive by the Oxford live cell-based assay were reviewed.

284 in RGS2 that cause loss of function (LOF) in cell-based assays were examined in isolated mouse arteri

285 The cell-based assays were most sensitive and specific overa

286 ompounds with high activity in cell-free and cell-based assays were obtained.

287 on rat brain and cultured neurons as well as cell-based assays were used to identify known autoantibo

288 e, a bridging ELISA, as well as a functional cell-based assay, were constructed.

289 We introduce a single-cell-based assay which allows us to control how fast the

290 125)I-alphaDTX-labelled Kv1 subunits, and by cell-based assays which expressed Kv1 subunits, LGI1 and

291 d well with those from mass spectrometry and cell-based assay, which are the industrial standards for

292 This sequential cell-based assay, which examines the monocyte and eBm5 c

293 and 5 kDa showed an inhibitory effect in the cell-based assay, while the fraction containing molecule

294 ling through G protein-dependent pathways in cell-based assays, while CXCL12-gamma had greatest effec

295 Cell-based assay with HEK293 expressing alpha1/beta3 sub

296 ed by automated fluorescence microscopy in a cell-based assay with murine macrophages.

297 e with rat hippocampal neuronal cultures and cell-based assays with known neuronal cell-surface antig

298 Use of cell-based assays with native MOG as the substrate enabl

299 Here, using cell-based assays with several Abeta species, including

300 SHMT in target assays and PfNF54 strains in cell-based assays with values in the low nanomolar range